Speciality pharmaceutical company CF PharmTech, which develops inhalation products for illnesses like asthma, is raising at least $72 million in pre-IPO funding, as investors see a profitable future in its treatments for chronic diseases.
The investment is expected to complete in the next few months, and funding will be used to accelerate CF PharmTech’s development. The company is expected to start selling its products in the second half of next year.
CF PharmTech is also planning an IPO in the next one to two years, after its products enter the market.
Established in 2008, the company has more than 20 projects...